The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of hospitalization for heart failure or cardiovascular (CV) death in adults following an acute myocardial infarction.
Low hemoglobin A1c and low body mass index are associated with higher risk for bone fracture in individuals with type 2 diabetes.
Higher intakes of vitamin C and carotenoids, as well as total whole grains, are associated with a lower risk for type 2 diabetes.
Several companies have initiated recalls of metformin extended-release tablets due to the possibility of unacceptable levels of N-Nitrosodimethylamine, a probable human carcinogen.
The list of conditions that put people at risk for severe COVID-19 illness has been expanded by the US Centers for Disease Control and Prevention.
Individuals with diabetes have an increased risk for hip and nonvertebral fractures.
Patients with type 2 diabetes who develop OSA are at higher risk for cardiovascular disease and other diabetes-related complications.
In patients who have type 2 diabetes and low cardiovascular risk, receiving metformin as first-line therapy appears justified.
Patients with type 2 diabetes have a greater risk for death after development of heart failure compared with other cardiovascular or renal diagnoses.
Adopting the 2019 Endocrine Society guidelines for diabetes screening would substantially increase the number of older adults classified as having T2D but would likely offer limited benefits.